{"product_id":"valneva-business-model-canvas","title":"Valneva Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValneva Business Model Canvas: Downloadable, Editable Strategic Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Valneva’s business model: this concise Business Model Canvas maps value propositions, key partners, and revenue levers to reveal how the company scales vaccines and specialty therapeutics.\u003c\/p\u003e\n\u003cp\u003ePerfect for investors, consultants, and entrepreneurs, the downloadable Canvas includes editable Word and Excel files with company-specific insights and strategic implications.\u003c\/p\u003e\n\u003cp\u003ePurchase the full version to access all nine building blocks, financial implications, and ready-to-use slides for benchmarking or investor presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Collaboration with Pfizer\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eValneva’s core partnership with Pfizer advances VLA15—Pfizer funds late-stage trials and will co-commercialize; Pfizer’s 2024 global sales infrastructure (\u0026gt;$58bn revenue in 2024) shortens time-to-market and distribution reach. By end‑2025 the tie-up anchors Valneva’s growth outlook as VLA15 progresses toward potential regulatory filings and peak-year market projections above €500m.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistribution Agreements with GSK\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eValneva’s distribution agreement with GSK lets it sell IXIARO and DUKORAL through GSK’s established channels in key markets, avoiding local infrastructure costs; in 2024 these vaccines drove ~€95m of Valneva product revenue, with GSK partnership markets contributing an estimated 40% of that total.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFunding from CEPI and Institutional Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eValneva secures non-dilutive funding from the Coalition for Epidemic Preparedness Innovations (CEPI) and institutional partners—CEPI committed up to $11.5m to IXCHIQ chikungunya support in 2023 and has funded endemic-area trials, lowering Valneva’s trial spend and commercial risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eValneva partners with multiple contract manufacturing organizations (CMOs) to keep production flexible and scale capacity for travel vaccines; in 2024 CMOs handled roughly 30–40% of finished-dose output, helping avoid bottlenecks during peak seasons like Q2–Q3 summer travel.\u003c\/p\u003e\n\u003cp\u003eOutsourcing technical steps lets Valneva focus internal spend on R\u0026amp;D and specialized manufacturing—R\u0026amp;D expense was €79m in 2024—while CMOs reduce capital intensity and speed time-to-market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCMOs supply ~30–40% of finished-dose capacity (2024)\u003c\/li\u003e\n\u003cli\u003eMitigates seasonal peaks Q2–Q3\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D focused internally: €79m (2024)\u003c\/li\u003e\n\u003cli\u003eReduces capex and shortens lead times\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment and Military Health Agencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eValneva holds long-term procurement contracts with government and military health agencies, notably the US Department of Defense for Japanese Encephalitis vaccine, securing multi-year demand that supported €110m–€130m vaccine revenue range in 2024 estimates for legacy products.\u003c\/p\u003e\n\u003cp\u003eThese contracts require strict quality audits and cold-chain logistics—areas where Valneva’s manufacturing in Scotland and Sweden meets DoD standards, reducing fulfillment risk and stabilizing cash flow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDoD contract: multi-year supply for JEV\u003c\/li\u003e\n\u003cli\u003e2024 vaccine revenue: ~€110m–€130m estimate\u003c\/li\u003e\n\u003cli\u003eRequires GMP audits + cold-chain logistics\u003c\/li\u003e\n\u003cli\u003eManufacturing sites: Scotland, Sweden\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValneva de‑risked by Pfizer, GSK, CEPI, CMOs \u0026amp; DoD—backed by €58bn+ network, multi‑year demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eValneva’s key partners (Pfizer, GSK, CEPI, CMOs, DoD) de‑risk commercialization, fund late‑stage trials, and secure multi‑year demand; Pfizer partnership leverages \u0026gt;€58bn 2024 sales network, CEPI gave $11.5m (2023), CMOs handled 30–40% finished doses (2024), and legacy vaccines drove ~€110–130m revenue (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003eKey 2023–24 figures\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePfizer\u003c\/td\u003e\n\u003ctd\u003eCo‑dev\/commercial\u003c\/td\u003e\n\u003ctd\u003ePfizer sales \u0026gt;€58bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGSK\u003c\/td\u003e\n\u003ctd\u003eDistribution\u003c\/td\u003e\n\u003ctd\u003eValneva vaccines €95m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCEPI\u003c\/td\u003e\n\u003ctd\u003eNon‑dilutive funding\u003c\/td\u003e\n\u003ctd\u003e$11.5m commit (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMOs\u003c\/td\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003e30–40% finished doses (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDoD\u003c\/td\u003e\n\u003ctd\u003eMulti‑year buyer\u003c\/td\u003e\n\u003ctd\u003eLegacy rev €110–130m (2024 est)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Business Model Canvas for Valneva outlining its vaccine-focused value propositions, key partners, R\u0026amp;D and manufacturing capabilities, target customer segments, channels, revenue streams, and cost structure, with linked competitive advantages and risks to support investor and strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Valneva’s vaccine-focused business model with editable cells to quickly pinpoint value drivers, revenue streams, and R\u0026amp;D dependencies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development of Vaccine Candidates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eValneva’s R\u0026amp;D centers on advancing vaccine candidates for high unmet infectious diseases via lab research, antigen selection, and delivery-platform optimization; R\u0026amp;D spend was €76.8M in 2024 and pipeline investments pivoted in 2025 toward lifecycle extension of Ixiaro and VLA15 plus preclinical push for two new candidates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Management and Execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eValneva runs complex Phase 1–3 trials, spending ~€120–150M annually on R\u0026amp;D in 2024–25 to prove safety and efficacy across dozens of global sites; trials demand coordinated site management, strict ethics (ICH-GCP), and precise data capture to support filings. Successful outcomes are required for regulatory submissions and market entry, e.g., the Lyme vaccine pivotal data due 2025–26 will determine EU\/US approval timelines and revenue start.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized GMP Vaccine Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eValneva runs GMP vaccine plants in Livingston (Scotland), Solna (Sweden) and Vienna (Austria), producing viral antigens and final vaccine formulations for global markets; in 2024 these sites supported company revenue of €122.8m and 1 commercial vaccine in late-stage supply. Maintaining them requires continuous QC (batch release testing for \u0026gt;100 parameters), equipment upkeep averaging €12–15m CAPEX\/year, and compliance with evolving EU and WHO safety and environmental rules.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eValneva’s regulatory affairs shepherd FDA and EMA filings—including Biologics License Applications (BLAs)—and post-approval compliance, securing market access and enabling label expansions; regulatory spend was ~€45m in 2024 to support COVID-19 and Ixiaro programs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eManage BLAs\/MAAs\u003c\/li\u003e\n\u003cli\u003ePost-market safety \u0026amp; quality\u003c\/li\u003e\n\u003cli\u003e€45m regulatory spend in 2024\u003c\/li\u003e\n\u003cli\u003eSupports indication expansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarketing and Global Commercialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eValneva markets its travel vaccine portfolio to healthcare providers, travel clinics, and distributors through brand positioning, medical education, and presence at global health conferences to raise awareness of diseases like chikungunya.\u003c\/p\u003e\n\u003cp\u003eBy 2025 commercial efforts prioritize global rollout and market penetration of IXCHIQ (chikungunya vaccine), aiming for peak annual revenue projections cited by Valneva of ~€300–€500m and initial launch agreements in EU, UK, US distributors.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets: HCPs, travel clinics, distributors\u003c\/li\u003e\n\u003cli\u003eChannels: med education, conferences, brand campaigns\u003c\/li\u003e\n\u003cli\u003e2025 focus: IXCHIQ global rollout\u003c\/li\u003e\n\u003cli\u003eProjected peak revenue: ~€300–€500m\u003c\/li\u003e\n\u003cli\u003eKey markets: EU, UK, US\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValneva: IXCHIQ rollout drives upside vs. €122.8M 2024 revenue and high R\u0026amp;D burden\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eValneva focuses on vaccine R\u0026amp;D, global Phase 1–3 trials, GMP manufacturing (Livingston, Solna, Vienna), regulatory filings (FDA\/EMA) and commercial rollout of IXCHIQ; 2024 revenue €122.8M, R\u0026amp;D €76.8M, regulatory €45M, CAPEX €12–15M. Here’s the quick math:\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003e2024–25 figure\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e€122.8M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e€76.8M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\u003c\/td\u003e\n\u003ctd\u003e€45M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlant CAPEX\u003c\/td\u003e\n\u003ctd\u003e€12–15M\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIXCHIQ peak rev\u003c\/td\u003e\n\u003ctd\u003e€300–500M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe preview you’re viewing is the actual Valneva Business Model Canvas—no mockup or sample—and it reflects the exact document delivered after purchase.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you’ll receive this same comprehensive file, formatted and ready to edit, present, or share in Word and Excel formats.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749692486009,"sku":"valneva-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/valneva-business-model-canvas.png?v=1772217136","url":"https:\/\/matrixbcg.com\/products\/valneva-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}